Merck reports tulisokibart results for Merck & Co. stock

Merck & Co. announced that its drug tulisokibart met primary and key secondary endpoints in a Phase 2b study for hidradenitis suppurativa, adding to its pipeline evidence. The company reported Q2 2026 revenue of $16.61 billion, a 5.10% increase year-over-year, and has a market capitalization of $359.1 billion. Despite a recent upfront payment of $400 million for a license agreement, analyst expectations remain divided, with some reiterating a Market Perform rating while others have increased pri